Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  New England Journal of Medicine

• Publication date

  2003-10-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA021933PMID 14561795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-Sm Autoantibodies in Systemic Lupus Target Highly Basic Surface Structures of Complexed Spliceosomal Autoantigens1

  2002cited by this paper
• Long-term outcome of mothers of children with isolated heart block in Finland.

  2001cited by this paper
• Development of Anti‐dsDNA Autoantibodies Prior to Clinical Diagnosis of Systemic Lupus Erythematosus

  2001cited by this paper
• Prediction and diagnosis of type 1 diabetes using beta-cell autoantibodies.

  2001cited by this paper
• Shared Early Autoantibody Recognition Events in the Development of Anti‐Sm B/B' in Human Lupus

  1999cited by this paper
• Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic.

  1998cited by this paper
• Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year

  1998cited by this paper
• Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

  1997cited by this paper
• The prevalence of antinuclear, anti-dsDNA, anti-Sm and anti-RNP antibodies in a group of healthy blood donors.

  1996cited by this paper
• The Prevalence of Antinuclear, Anti-dsDNA, Anti-Sm and Anti-RNP Antibodies in a Group of Healthy Blood Donors

  1996cited by this paper
• Long-term outcome of mothers of children with complete congenital heart block.

  1996cited by this paper
• Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity

  1995cited by this paper
• One Hundred Anti‐Ro (SS‐A) Antibody Positive Patients: A 10‐Year Follow‐Up

  1995cited by this paper
• Development of anti-Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with long-standing Sjögren's syndrome

  1995cited by this paper
• Review : Serological markers of disease activity in systemic lupus erythematosus

  1995cited by this paper
• Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies

  1995cited by this paper
• Statistical Methods for Survival Data Analysis

  1994cited by this paper
• Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La.

  1993cited by this paper
• Antinuclear antibodies heralding the onset of systemic lupus erythematosus.

  1992cited by this paper
• Plasma concentration of IL‐6 in systemic lupus erythematosus; an indicator of disease activity?

  1992cited by this paper
• Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus.

  1992cited by this paper
• Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus.

  1992cited by this paper
• Rheumatoid factors antedating clinical rheumatoid arthritis.

  1991cited by this paper
• Dubois' Lupus Erythematosus

  1987cited by this paper
• Measurement of anti-DNA antibodies: a reappraisal using five different methods.

  1987cited by this paper
• Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

  1987cited by this paper
• Implications of anti-Ro/Sjögren's syndrome A antigen autoantibody in normal sera for autoimmunity.

  1987cited by this paper
• [Antibodies to Ro(SSA) and La(SSB) antigens in Sjögren's disease and syndrome].

  1987cited by this paper
• The 1982 revised criteria for the classification of systemic lupus erythematosus.

  1982cited by this paper
• Systemic lupus erythematosus.

  1977cited by this paper
• IMMUNOLOGY OF DNA. III. CRITHIDIA LUCILIAE, A SIMPLE SUBSTRATE FOR THE DETERMINATION OF ANTI‐dsDNA WITH THE IMMUNOFLUORESCENCE TECHNIQUE *

  1975cited by this paper
• [Erythematosus].

  1971cited by this paper
• Lupus erythematosus : a review of the current status of discoid and systemic lupus erythematosus and their variants

  1966cited by this paper
• A generalized two-sample Wilcoxon test for doubly censored data.

  1965cited by this paper
• A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

  1965cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• [Systemic lupus erythematosus].

  1955cited by this paper
• SYSTEMIC LUPUS ERYTHEMATOSUS: REVIEW OF THE LITERATURE AND CLINICAL ANALYSIS OF 138 CASES

  1954cited by this paper

• Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review

  2026cites this paper
• Restoring B cell intrinsic tolerance to lupus autoimmunity: a rational strategy for lupus treatment.

  2026cites this paper
• A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus

  2026cites this paper
• Causation-based SLE diagnostic criteria should replace advance-repressing SLE classification criteria.

  2026cites this paper
• Type I interferon-dependent and -independent signaling underlie autoantibody production in a murine lupus model

  2026cites this paper
• Spinal fluid antibody profile against bacteria demonstrates intrathecal antibody production in demyelinating diseases

  2026cites this paper
• Mechanistic insights into B-cell activation and autoreactivity regulation in active SLE and remission

  2026cites this paper
• Autoantibodies as Precision Tools in Connective Tissue Diseases: From Epiphenomenon to Endophenotype

  2026cites this paper
• RAPIDLY PROGRESSING SYSTEMIC LUPUS ERYTHEMATOSUS IN A YOUNG PATIENT

  2026cites this paper
• Oligoprotein type I interferon signatures, but not TREX1 variants, increase risk of systemic lupus erythematosus in UK Biobank

  2026cites this paper
• Evaluation of Anti-dsDNA Antibodies in Laboratory Practice: Management of Different Analytical Methods and Correlation with HEp-2 Immunofluorescence Patterns

  2026cites this paper
• Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review.

  2026cites this paper
• Plasmablast Storms: Microbial Drivers of Acute and Chronic Autoimmune Flares

  2026cites this paper
• Patients with recent-onset systemic lupus erythematosus use more antidepressant medication than matched controls: A case–control study

  2026cites this paper
• Pitfalls of autoimmune serological markers and practical diagnostic workflows in connective tissue diseases and rheumatoid arthritis.

  2026cites this paper
• Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment.

  2026cites this paper
• Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.

  2026cites this paper
• Signal or noise? Apply myositis autoantibody line-blot immunoassays in real-world settings: implications for diagnostic accuracy

  2026cites this paper
• A study of clinical manifestations and associated factors in photosensitive patients with systemic lupus erythematosus

  2026cites this paper
• Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis

  2026cites this paper
• The Antibody-Microbiota Interface in Autoimmune Diseases.

  2026cites this paper
• Recruitment of Enzymatic Labels via Glycan-Lectin Interactions for Electrochemical Immunosensing of Anti-dsDNA Antibodies.

  2026cites this paper
• Autoreactomes in Healthy Individuals Vary According to HLA Class II Genotype

  2026cites this paper
• Roads and detours for CAR T cell therapy in autoimmune diseases.

  2026cites this paper
• Delays in Lupus Diagnosis and Treatment in the Southern Cone: A Qualitative Study of Patient and Rheumatologist Perspectives.

  2025cites this paper
• Blood DNA virome associates with autoimmune diseases and COVID-19

  2025cites this paper
• Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations.

  2025cites this paper
• The role of IRF-1 in mediating T-cell immune imbalance in systemic lupus erythematosus and the construction of a diagnostic model

  2025cites this paper
• Autoantibody-defined subsets of patients with systemic lupus erythematosus associate with clinical manifestations, NCF2, and HLA DR3-DQ2 genotypes.

  2025cites this paper
• Type 1 Diabetes and Other Autoimmune Diseases—Epidemiology, Pathophysiology and Screening

  2025cites this paper
• Analytical and clinical comparison of four SLE-associated autoantibodies in different autoimmune diseases

  2025cites this paper
• Association of serum complement C3 level with disease severity in primary pterygium

  2025cites this paper
• Association of Blood–Brain Barrier Function With Disease Activity and Cognitive Function in Systemic Lupus Erythematosus Patients

  2025cites this paper
• High interferon response signatures in SLE patient leukocytes are associated with increased transposable element expression in gene introns and intergenic regions

  2025cites this paper
• Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management.

  2025cites this paper
• Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights

  2025cites this paper
• Primordial and primary prevention in rheumatological diseases: The time has come.

  2025cites this paper
• ScreeningLessons from Prediction and Prevention of Type 1 Diabetes.

  2025cites this paper
• Type I interferon as a pre‐lupus marker in anti‐nuclear antibody‐associated childhood immune thrombocytopenic purpura

  2025influential citation
• Nailfold capillaroscopy. Where are we going?

  2025cites this paper
• Prepubertal to adolescent lupus: Age-related variations in clinical, laboratory, and outcome profiles

  2025cites this paper
• Distinct interferon response patterns link to increased transposable element expression in leukocytes of systemic lupus erythematosus patients

  2025cites this paper
• Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus

  2025influential citation
• Maternal imprinting of autoreactivity in a murine model of systemic lupus erythematosus.

  2025cites this paper
• Cognitive Dysfunction in Systemic Lupus Erythematosus During Pregnancy

  2025cites this paper
• CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon

  2025cites this paper
• Systemic lupus erythematosus‐associated autoantibodies in sickle cell disease: Spontaneous emergence in a patient and in transgenic sickle mice

  2025cites this paper
• RIPK3 impacts antibody generation in an induced model of murine lupus through mechanisms other than necroptosis and antigen presentation

  2025cites this paper
• B cell subpopulations and their role in the pathogenesis of primary Sjögren’s syndrome: insights from single-cell RNA sequencing

  2025cites this paper
• Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells

  2025cites this paper
• Integrating electronic health records and GWAS summary statistics to predict the progression of autoimmune diseases from preclinical stages

  2025cites this paper
• VEXAS syndrome presenting with features of Sjögren’s disease: a case-based review of VEXAS and autoimmune disease overlap

  2025cites this paper
• Understanding IgE-mediated autoimmunity and autoallergy.

  2025cites this paper
• C1q Is Recognized as a Soluble Autoantigen by Anti-C1q Antibodies of Patients with Systemic Lupus Erythematosus

  2025cites this paper
• Effect of Age on Xenobiotic-Induced Autoimmunity

  2025cites this paper
• B cell-targeted therapies in systemic lupus erythematosus: Current status and perspectives.

  2025cites this paper
• Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review.

  2025cites this paper
• Enhancing the treatment potential of IL-17 antagonism in lupus nephritis: finding the right partner

  2025cites this paper
• Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy

  2025cites this paper
• Rheumatic autoimmune disease in relation to post-traumatic stress disease and traumatic brain injury

  2025cites this paper
• New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?

  2025cites this paper
• Undifferentiated connective tissue disease: the diagnoses critically revised-experience of a single center

  2025cites this paper
• Systemische Autoimmunerkrankungen bei Kindern

  2025cites this paper
• Clinical features of antibody-negative autoimmune encephalitis: A meta-analysis and literature review

  2025cites this paper
• Capilaroscopia del lecho ungular: ¿hacia dónde vamos?

  2025cites this paper
• Increased healthcare utilisation in the 5 years preceding systemic lupus erythematosus diagnosis: a Danish nationwide cohort study.

  2025cites this paper
• Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”

  2025cites this paper
• Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from Sweden

  2025cites this paper
• Just Autoimmunity? The Role of the Innate Immune Response in Lupus.

  2025cites this paper
• Small RNA and Toll-like receptor interactions: origins and disease mechanisms.

  2025cites this paper
• Defining immune reset: achieving sustained remission in autoimmune diseases

  2025cites this paper
• A cohort of highly activated CD99- CD72+ B cells promoting autoimmune progression in juvenile systemic lupus erythematosus.

  2025cites this paper
• Cardiac autoantibodies promote a fibrotic transcriptome and reduced ventricular recovery in human myocarditis

  2025cites this paper
• Monozygotic twins discordant for juvenile dermatomyositis: clinical, serological and gene expression studies

  2025cites this paper
• New Insights Into the Multistage Development of Rheumatoid Arthritis

  2025cites this paper
• Prevalence of Rheumatoid Factor and Anti-citrullinated Protein Antibodies in Patients With Post-treatment Lyme Disease

  2025cites this paper
• The Current and Future of Biomarkers of Immune Related Adverse Events.

  2025cites this paper
• Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study

  2025cites this paper
• Unmet needs in autoimmune liver diseases.

  2025cites this paper
• Crystalline silica exposure induces multiple systemic autoimmune phenotypes including inflammatory arthritis and nephritis in Collaborative Cross mice with differing sub-clinical autoimmune profiles.

  2025cites this paper
• Early diagnosis of systemic lupus erythematosus

  2025cites this paper
• Exploring Key Genes of Glutathione Metabolism in Systemic Lupus Erythematosus Based on Mendelian Randomisation, Single‐Cell RNA Sequencing and Multiple Machine Learning Approaches

  2025cites this paper
• Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion

  2025cites this paper
• Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease

  2025cites this paper
• Crosstalk Between Oxidative Stress, Mitochondrial Dysfunction, Chromosome Instability, and the Activation of the cGAS-STING/IFN Pathway in Systemic Sclerosis.

  2025cites this paper
• EBV and Autoimmunity.

  2025cites this paper
• Genome-wide association study for loci associated with positive antinuclear antibodies.

  2025cites this paper
• Neuroimmune mechanisms of neuropsychiatric systemic lupus erythematosus.

  2025cites this paper
• A Systemic Lupus Erythematosus Incidence Surveillance Report Among DoD Beneficiaries During the COVID-19 Pandemic.

  2025cites this paper
• Differences in IgG Sialylation Distinguish Asymptomatic From Symptomatic Antinuclear Antibody–Positive Individuals

  2025cites this paper
• The Art of Interpreting Antinuclear Antibodies (ANAs) in Everyday Practice

  2025cites this paper
• REDEFINING AUTOIMMUNE DISEASES: THE OPPORTUNITY FOR PRECISION AND PREVENTION.

  2025cites this paper
• Can we cure lupus?

  2025cites this paper
• Evaluating the performance of four anti-dsDNA antibody detection methods

  2025cites this paper
• Polyautoimmunity Reflecting Immune Dysregulation in Common Variable Immunodeficiency

  2025cites this paper
• RNA sensing at the crossroads of autoimmunity and autoinflammation

  2025cites this paper
• Glycan-Evoked Silver Deposition for Highly Sensitive Electrochemical Assay of Anti-dsDNA Antibodies.

  2025cites this paper
• Trained immunity induced by DAMPs and LAMPs in chronic inflammatory diseases

  2025cites this paper
• Novel RSAD2 isoforms lacking antiviral activities are originated from alternative splicing and expressed in patients with rheumatic diseases.

  2025cites this paper
• T cell-B cell interactions in human autoimmune diseases.

  2025cites this paper